Understanding Chronic Kidney Disease in Patients with Type 2 Diabetes

Chronic kidney disease (CKD) is diagnosed by the persistent elevation of urinary albumin excretion (albuminuria), low estimated glomerular filtration rate (eGFR) or other manifestations of kidney damage. Diabetes-related kidney disease typically develops after a diabetes duration of 10 years in type 1 diabetes but may be present at diagnosis of type 2 diabetes. In addition, among people with type 1 or type 2 diabetes, the presence of CKD markedly increases cardiovascular risk.

<table>
<thead>
<tr>
<th>Top 5 CKD Treatment Recommendations:</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
</tr>
<tr>
<td>2</td>
</tr>
<tr>
<td>3</td>
</tr>
<tr>
<td>4</td>
</tr>
<tr>
<td>5</td>
</tr>
</tbody>
</table>

See reverse side for additional information →
Treating Chronic Kidney Disease in Patients with Type 2 Diabetes

1 **Blood Glucose Management**

Optimize blood glucose management to reduce the risk or slow the progression of CKD. Targets are:

- **A1C**: Less than 7%
- **eAG**: Less than 154 mg/dL
- **Before a meal**: 80–130 mg/dL
- **1–2 hours after beginning of the meal**: Less than 180 mg/dL

An ACE inhibitor or an ARB is not recommended for the primary prevention of CKD in people with diabetes who have normal blood pressure, normal UACR (<30 mg/g creatinine), normal eGFR or are pregnant or plan to become pregnant.

Do not discontinue renin-angiotensin system blockade for increases in serum creatinine (≤30%) in the absence of volume depletion.

**Glucose-lowering therapy**:

Recommend a sodium-glucose cotransporter 2 inhibitor to reduce CKD progression and cardiovascular events in patients with an eGFR ≥20 mL/min/1.73 m² and UACR ≥200 mg/g.

**Nonsteroidal mineralocorticoid receptor antagonist**:

Recommend in people with CKD and albuminuria who are at increased risk for cardiovascular events or CKD progression.

2 **Blood Pressure Management**

Optimize blood pressure management and reduce blood pressure variability to lower the risk or slow the progression of CKD. A healthy blood pressure is below 120/80.

An ACE inhibitor or an ARB is not recommended for the primary prevention of CKD in people with diabetes who have normal blood pressure, normal UACR (<30 mg/g creatinine), normal eGFR or are pregnant or plan to become pregnant.

Do not discontinue renin-angiotensin system blockade for increases in serum creatinine (≤30%) in the absence of volume depletion.

**Glucose-lowering therapy**:

Recommend a sodium-glucose cotransporter 2 inhibitor to reduce CKD progression and cardiovascular events in patients with an eGFR ≥20 mL/min/1.73 m² and UACR ≥200 mg/g.

**Nonsteroidal mineralocorticoid receptor antagonist**:

Recommend in people with CKD and albuminuria who are at increased risk for cardiovascular events or CKD progression.

3 **Pharmacologic Interventions**

Consider pharmacologic interventions, including:

**Angiotensin-converting enzyme (ACE) or angiotensin receptor blocker (ARB):**

Recommend for those with moderately increased albuminuria: urinary albumin-to-creatinine ratio (UACR) 30–299 mg/g creatinine.

Strongly recommended for those with severely increased albuminuria: UACR ≥300 mg/g creatinine and/or (eGFR) of <60 mL/min/1.73 m².

Monitor serum creatinine and potassium levels periodically for the development of increased creatinine and hyperkalemia when ACE inhibitors, ARBs and mineralocorticoid receptor antagonists are used, or hypokalemia when diuretics are used.

4 **Lifestyle Interventions**

Discuss lifestyle interventions, including:

Setting target for dietary protein intake of 0.8 g/kg body weight per day for people with non-dialysis-dependent stage 3 or higher CKD.

Taking in higher levels of dietary protein for patients on dialysis, since protein energy wasting is a major problem in some individuals.

5 **Nephrologist Referral**

Refer to a nephrologist for uncertainty about the etiology of kidney disease, difficult management issues, and rapidly progressing kidney disease.

---

Learn more with the **Cardiovascular Disease in Type 2 Diabetes for Health Care Professionals** course. Find out more at [KnowDiabetesbyHeart.org/CVDinType2Course](http://KnowDiabetesbyHeart.org/CVDinType2Course)

---

Copyright 2023 American Diabetes Association®, a 501(c)(3) not-for-profit. All rights reserved. Know Diabetes by Heart™ is a trademark of the American Heart Association® and American Diabetes Association®. Unauthorized use prohibited.